May 27, 2022 07:40 AM EDT
R&D

Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

Amber Tong

As the close run­ner-up to Am­gen’s Lumakras in the KRAS race, any da­ta cut from Mi­rati’s ada­gra­sib con­tin­ues to draw scruti­ny from an­a­lysts. And the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

A service from the Financial Times